Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HTR3A | P46098 | 10/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.59 |
| ▸ | HTR3B | O95264 | 7/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirisetron SCHEMBL194840 | 1.00 | KDM4E (0.61) | KDM4EMEN1KMT2AHTR3AHTR3E | |
| Mirisetron SCHEMBL194841 | 1.00 | KDM4E (0.61) | KDM4EMEN1KMT2AHTR3AHTR3E | |
| SCHEMBL9029352 | 0.96 | HTR3A (0.63) | KDM4EMEN1KMT2AHTR3AHTR3E | |
| Mirisetron SCHEMBL121861 | 0.94 | KDM4E (0.58) | KDM4EMEN1KMT2AHTR3AHTR3E | |
| Mirisetron SCHEMBL121862 | 0.94 | KDM4E (0.58) | KDM4EMEN1KMT2AHTR3AHTR3E | |
| Mirisetron SCHEMBL7362107 | 0.94 | KDM4E (0.58) | KDM4EMEN1KMT2AHTR3AHTR3E | |
| Mirisetron SCHEMBL678308 | 0.94 | KDM4E (0.58) | KDM4EMEN1KMT2AHTR3AHTR3E | |
| SCHEMBL9028258 | 0.86 | HTR3A (0.60) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL9027434 | 0.86 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL16378030 | 0.83 | CNR1 (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0494978-B1 | HETEROCYCLIC COMPOUNDS | WYETH JOHN & BROTHER LTD (GB) | 1996-02-28 | — | — | EP | claimed |
| WO-1995001793-A2 | 5-HT-3-ANTAGONISTS AS TOPICAL MEDICAMENTS FOR TREATMENT OF PERIPHERAL DISORDERS ASSOCIATED WITH PAIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-19 | — | — | WO | claimed |
| EP-0494978-A1 | HETEROCYCLIC COMPOUNDS. | WYETH JOHN & BROTHER LTD (GB) | 1992-07-22 | — | — | EP | claimed |
| US-5096901-A | PHARMACOLOGICALLY ACTIVE AMIDES AND ESTERS CONTAINING AN AZABICYCLOALKANE MOIETY | JOHN WYETH & BROTHER LIMITED (GB) | 1992-03-17 | — | — | US | claimed |
| WO-1991005783-A1 | HETEROCYCLIC COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1991-05-02 | — | — | WO | claimed |
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-0851756-B1 | USE OF ONDANSETRON IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TREMOR | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | EP | disclosed |
| EP-1239882-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045685-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-0851756-A1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997010823-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1997-03-27 | — | — | WO | disclosed |
| EP-0494978-B1 | HETEROCYCLIC COMPOUNDS | WYETH JOHN & BROTHER LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| WO-1995001793-A3 | 5-HT-3-ANTAGONISTS AS TOPICAL MEDICAMENTS FOR TREATMENT OF PERIPHERAL DISORDERS ASSOCIATED WITH PAIN | AMERICAN HOME PROD (US) | 1995-03-30 | — | — | WO | disclosed |
| WO-1995001793-A2 | 5-HT-3-ANTAGONISTS AS TOPICAL MEDICAMENTS FOR TREATMENT OF PERIPHERAL DISORDERS ASSOCIATED WITH PAIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-19 | — | — | WO | disclosed |
| WO-1995001793-A2 | 5-HT-3-ANTAGONISTS AS TOPICAL MEDICAMENTS FOR TREATMENT OF PERIPHERAL DISORDERS ASSOCIATED WITH PAIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-19 | — | — | WO | disclosed |
| US-5362734-A | Certain benzo-quinolizine compounds and derivatives thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | disclosed |
| US-5225419-A | Antagonist 5-hydroxytryptamine for treatment of nausea or vomiting | JOHN WYETH & BROTHER, LIMITED (GB) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018008-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA3, ADORA2A | KDM4E 3640/4885MEN1 870/4885KMT2A 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.